Metabolite Profiling and Identification in IBD Drug Discovery

Metabolite profiling and identification are qualitative and quantitative studies of drug biotransformation in non-clinical animals and humans. These studies include metabolite search and structure elucidation, pathway characterization, and metabolite relative abundance determination. The identification of metabolic pathways of drug candidates plays a key role in drug discovery, preclinical and clinical development. Insights into the pharmacokinetics and safety of compounds can be gained through a better understanding of the metabolic profile of IBD drugs.

Fig. 1. Deletion of mucin 2 induces colitis with concomitant metabolic abnormalities in mice. (Ishida et al., 2018)

Our Metabolite Profiling and Identification Services

Ace Therapeutics provides comprehensive metabolite profiling and identification services to profile, isolate, analyze and identify metabolites in support of IBD drug discovery and safety studies.

Our ADME experts have extensive expertise in a variety of techniques, including liquid chromatography (LC)-high resolution mass spectrometry (HRMS), chemically intelligent software algorithms, mass spectrometry imaging, ultraviolet (UV), radiometric detection, and nuclear magnetic resonance (NMR). These methods allow for a more pragmatic, multidisciplinary approach to answering key questions about the biotransformation and metabolism of IBD drugs, helping you take compounds from concept to drug candidate.

Our capabilities include:

• Radio-synthesis of ³H or ¹⁴C-labelled compounds
• Isolation and purification of metabolites
• Metabolite structure elucidation
• Metabolic soft-spot determination
• Cross-species metabolite characterization using liver microsomes and hepatocytes with unlabeled and radiolabeled test compounds
• Mechanistic studies (reactive metabolites, mechanism of chiral inversion, etc.)
• In vivo metabolite profiling and identification in rodent and large animal species
• Safety testing of metabolites

Why Choose Us

• We can analyze metabolites that may be formed to support your pharmacological, pharmacokinetic and toxicological studies of IBD drugs.
• We provide advanced multi-combinatorial techniques to determine the precise quality of any metabolite at high resolution.
• We can study metabolites in different matrices, including in-vitro microsomal incubations, hepatocyte incubations, expressed enzyme incubations as well as in vivo samples (plasma, urine, and other matrices).
• Reports are project-specific, depending on the nature of the project, ranging from simple tables of proposed structures to providing extracted ion chromatograms, MS and MS/MS spectra, and interpretation of the data for each metabolite.

Ace Therapeutics has the capability to perform metabolite profiling and identification studies on early IBD drug development in vitro samples and in vivo samples from animal studies. Our team of scientists designs bespoke experiments to help our client partners overcome their unique and complex challenges when it comes to IBD drug metabolism studies. If you are interested in our services, please do not hesitate to contact us.